Kailera Therapeutics (NASDAQ:KLRA) Stock Breaks Above Fifty Day Moving Average – What’s Next?

Kailera Therapeutics, Inc. (NASDAQ:KLRA)’s stock price passed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $12.78 and traded as high as $13.26. Kailera Therapeutics shares last traded at $12.97, with a volume of 733,039 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Kailera Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research note on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $42.75.

Kailera Therapeutics Stock Performance

The stock has a fifty day moving average price of $12.78. The firm has a market cap of $1.68 billion and a price-to-earnings ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($1.55) by $0.81. As a group, sell-side analysts forecast that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kailera Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Atlas Venture Life Science Advisors LLC purchased a new stake in shares of Kailera Therapeutics during the second quarter valued at approximately $113,923,000. Wellington Management Group LLP acquired a new position in Kailera Therapeutics during the 2nd quarter worth $64,308,000. Frazier Life Sciences Management L.P. bought a new stake in shares of Kailera Therapeutics in the 2nd quarter valued at approximately $24,233,000. State Street Corp acquired a new position in Kailera Therapeutics during the second quarter valued at approximately $19,126,000. Finally, Aberdeen Group plc increased its holdings in Kailera Therapeutics by 209.0% in the 3rd quarter. Aberdeen Group plc now owns 432,661 shares of the company’s stock worth $4,941,000 after purchasing an additional 292,661 shares in the last quarter.

Kailera Therapeutics Company Profile

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and related metabolic diseases.

The company’s activities center on the research and development of potential pharmaceutical therapies intended to address chronic weight management and associated health conditions. Its products remain in development and are subject to clinical, regulatory and commercial milestones.

Publicly available information about Kailera Therapeutics’ specific product candidates, operating geographies and leadership is limited.